CR20240004A - Composición farmacéutica de virus no encapsulado - Google Patents

Composición farmacéutica de virus no encapsulado

Info

Publication number
CR20240004A
CR20240004A CR20240004A CR20240004A CR20240004A CR 20240004 A CR20240004 A CR 20240004A CR 20240004 A CR20240004 A CR 20240004A CR 20240004 A CR20240004 A CR 20240004A CR 20240004 A CR20240004 A CR 20240004A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical composition
compositions
virus
unencapsulated
unencapsulated virus
Prior art date
Application number
CR20240004A
Other languages
English (en)
Spanish (es)
Inventor
Ekaterina Aleksandrovna Lomkova
Aleksandra Aleksandrovna Sozonova
Lina Igorevna Fedorenko
Dmitry Valentinovich Morozov
Aleksandr Olegovich Iakovlev
Marina Konstantinovna Dvoriankina
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021120143A external-priority patent/RU2860958C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of CR20240004A publication Critical patent/CR20240004A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CR20240004A 2021-07-08 2022-07-04 Composición farmacéutica de virus no encapsulado CR20240004A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021120143A RU2860958C2 (ru) 2021-07-08 Фармацевтическая композиция безоболочечного вируса
PCT/RU2022/050212 WO2023282796A2 (fr) 2021-07-08 2022-07-04 Composition pharmaceutique de virus non enveloppé

Publications (1)

Publication Number Publication Date
CR20240004A true CR20240004A (es) 2024-06-11

Family

ID=84800844

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240004A CR20240004A (es) 2021-07-08 2022-07-04 Composición farmacéutica de virus no encapsulado

Country Status (12)

Country Link
EP (1) EP4367252A4 (fr)
CN (1) CN117999353A (fr)
AR (1) AR126417A1 (fr)
CL (1) CL2024000062A1 (fr)
CO (1) CO2024000073A2 (fr)
CR (1) CR20240004A (fr)
EC (1) ECSP24001599A (fr)
JO (1) JOP20240003A1 (fr)
MA (1) MA63861A1 (fr)
MX (1) MX2024000472A (fr)
WO (1) WO2023282796A2 (fr)
ZA (1) ZA202400124B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026503893A (ja) * 2023-01-19 2026-02-02 ユニキュアー バイオファーマ ビー.ブイ. 遺伝子送達媒体の医薬製剤
TW202525313A (zh) * 2023-09-06 2025-07-01 瑞士商迪納柯公司 用aav基因治療載體及治療調配物治療肥厚性心肌病之方法
WO2025114524A1 (fr) * 2023-11-30 2025-06-05 Uniqure Biopharma B.V. Formulations pour produits médicamenteux viraux
WO2025263459A1 (fr) * 2024-06-17 2025-12-26 学校法人神戸薬科大学 Composition biopharmaceutique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120219590A1 (en) * 2011-02-24 2012-08-30 Paxvax, Inc. Formulations useful for spray drying vaccines
US20130216499A1 (en) * 2012-02-17 2013-08-22 Wenlin Huang Compositions of recombinant human endostatin adenovirus injections and methods of production
JP6013654B2 (ja) * 2013-09-19 2016-10-25 クルセル ホランド ベー ヴェー 改良されたアデノウイルス製剤
BR112019009113A2 (pt) * 2016-11-04 2019-07-16 Baxalta Incorporated formulações de vírus adenoassociado
CN112770812A (zh) * 2018-07-24 2021-05-07 沃雅戈治疗公司 产生基因治疗制剂的系统和方法

Also Published As

Publication number Publication date
MA63861A1 (fr) 2024-10-31
ZA202400124B (en) 2024-11-27
EP4367252A4 (fr) 2025-04-30
WO2023282796A2 (fr) 2023-01-12
EP4367252A2 (fr) 2024-05-15
JOP20240003A1 (ar) 2024-01-08
MX2024000472A (es) 2024-02-12
AR126417A1 (es) 2023-10-11
ECSP24001599A (es) 2024-02-29
CL2024000062A1 (es) 2024-06-14
CN117999353A (zh) 2024-05-07
CO2024000073A2 (es) 2024-04-29
WO2023282796A3 (fr) 2023-02-16

Similar Documents

Publication Publication Date Title
CR20240004A (es) Composición farmacéutica de virus no encapsulado
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
MX2021004431A (es) Procesos novedosos.
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
BR112018006074A2 (pt) vetores de fator viii de vírus adeno-associado, partículas virais associadas e formulações terapêuticas compreendendo as mesmas
WO2015128403A3 (fr) Nouveaux dérivés de l'insuline et leurs utilisations médicales
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
EP3498279A4 (fr) Composition pharmaceutique comprenant comme principes actifs de l'amodiaquine et un médicament anti-diabète, destinée à la prévention ou le traitement du diabète
EA201892493A1 (ru) Жидкая композиция нейротоксина, стабилизированная триптофаном или тирозином
EA201891941A1 (ru) Профилактическая лечебная композиция на основе пероксометаллата, в частности фармацевтическая композиция
EP4477267A3 (fr) Compositions médicamenteuses à base de collagène peptidique pour l'utilisation dans le traitement des maladies, troubles ou blessures oculaires
WO2022192594A3 (fr) Molécules d'acide nucléique et vaccins les comprenant pour la prévention et le traitement d'infections à coronavirus et de maladie
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
WO2020219486A3 (fr) Compositions médicamenteuses à base de collagène peptidique et dispositifs et procédés pour les produire et les utiliser
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
BR112015023806A2 (pt) Novos regimes de dosagem de celgosivir para o tratamento de dengue
EA202090666A1 (ru) Применение содержащей бензоат композиции для лечения глициновой энцефалопатии
PH12022551094A1 (en) Novel insulin analogues and uses thereof
PH12022550238A1 (en) Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations
CO2023004031A2 (es) Administración sistémica del vector de virus adenoasociado que expresa el sarcoglucano g y el tratamiento de la distrofia muscular
BR112019024796A2 (pt) Peptídeos e usos dos mesmos como agentes antivirais
MX2024009890A (es) Factores terapeuticos para el tratamiento de enfermedades poliglutaminicas
GEAP202516788A (en) Pharmaceutical composition of non-enveloped virus
BR112017022390A2 (pt) composição farmacêutica
BR112017015474A2 (pt) inibidores de bace1